{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T05:22:38Z","timestamp":1780377758406,"version":"3.54.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2020R1G1A1102672"],"award-info":[{"award-number":["2020R1G1A1102672"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Korea Health Technology R&D Project through the Korea Health Industry Development Institute","award":["HR22C1832"],"award-info":[{"award-number":["HR22C1832"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00280-024-04670-8","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T08:02:01Z","timestamp":1713859321000},"page":"103-108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Exploring the effect of BRCA1\/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer"],"prefix":"10.1007","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0139-9768","authenticated-orcid":false,"given":"In Hee","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gun Oh","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Mi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dea Gy","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8585-4982","authenticated-orcid":false,"given":"Yee Soo","family":"Chae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"issue":"5","key":"4670_CR1","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1158\/1078-0432.Ccr-12-2243","volume":"19","author":"S Banerjee","year":"2013","unstructured":"Banerjee S, Kaye SB (2013) New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 19(5):961\u2013968. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-12-2243","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4670_CR2","doi-asserted-by":"publisher","first-page":"562","DOI":"10.6004\/jnccn.2010.0043","volume":"8","author":"MB Daly","year":"2010","unstructured":"Daly MB, Axilbund JE, Buys S, Crawford B, Farrell CD, Friedman S, Garber JE, Goorha S, Gruber SB, Hampel H, Kaklamani V, Kohlmann W, Kurian A, Litton J, Marcom PK, Nussbaum R, Offit K, Pal T, Pasche B, Pilarski R, Reiser G, Shannon KM, Smith JR, Swisher E, Weitzel JN (2010) Genetic\/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw 8(5):562\u2013594. https:\/\/doi.org\/10.6004\/jnccn.2010.0043","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"4670_CR3","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A (2004) Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat Rev Cancer 4(10):814\u2013819. https:\/\/doi.org\/10.1038\/nrc1457","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"4670_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/nrc.2016.72","volume":"16","author":"FC Nielsen","year":"2016","unstructured":"Nielsen FC, van Overeem Hansen T, Sorensen CS (2016) Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer 16(9):599\u2013612. https:\/\/doi.org\/10.1038\/nrc.2016.72","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4670_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrc2342","volume":"8","author":"T Helleday","year":"2008","unstructured":"Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA (2008) DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 8(3):193\u2013204. https:\/\/doi.org\/10.1038\/nrc2342","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4670_CR6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrm2858","volume":"11","author":"S Negrini","year":"2010","unstructured":"Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability\u2013an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11(3):220\u2013228. https:\/\/doi.org\/10.1038\/nrm2858","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"25","key":"4670_CR7","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O\u2019Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Perez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ, Investigators PE-OG- (2019) Niraparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med 381(25):2391\u20132402. https:\/\/doi.org\/10.1056\/NEJMoa1910962","journal-title":"N Engl J Med"},{"issue":"26","key":"4670_CR8","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, Gonzalez-Martin A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P (2018) Maintenance Olaparib in patients with newly diagnosed Advanced Ovarian Cancer. N Engl J Med 379(26):2495\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1810858","journal-title":"N Engl J Med"},{"issue":"25","key":"4670_CR9","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, Fujiwara K, Vergote I, Colombo N, Maenpaa J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marme F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P, Investigators P- (2019) Olaparib plus Bevacizumab as First-Line maintenance in Ovarian Cancer. N Engl J Med 381(25):2416\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1911361","journal-title":"N Engl J Med"},{"issue":"5","key":"4670_CR10","doi-asserted-by":"publisher","first-page":"100238","DOI":"10.1016\/j.esmoop.2021.100238","volume":"6","author":"G Orsi","year":"2021","unstructured":"Orsi G, Di Marco M, Cavaliere A, Niger M, Bozzarelli S, Giordano G, Noventa S, Rapposelli IG, Garajova I, Tortora G, Rodriquenz MG, Bittoni A, Penzo E, De Lorenzo S, Peretti U, Paratore C, Bernardini I, Mosconi S, Spallanzani A, Macchini M, Tamburini E, Bencardino K, Giommoni E, Scartozzi M, Forti L, Valente MM, Militello AM, Cascinu S, Milella M, Reni M (2021) Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey. ESMO Open 6(5):100238. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100238","journal-title":"ESMO Open"},{"issue":"4","key":"4670_CR11","doi-asserted-by":"publisher","first-page":"R110","DOI":"10.1186\/bcr3231","volume":"14","author":"T Byrski","year":"2012","unstructured":"Byrski T, Dent R, Blecharz P, Foszczynska-Kloda M, Gronwald J, Huzarski T, Cybulski C, Marczyk E, Chrzan R, Eisen A, Lubinski J, Narod SA (2012) Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 14(4):R110. https:\/\/doi.org\/10.1186\/bcr3231","journal-title":"Breast Cancer Res"},{"issue":"20","key":"4670_CR12","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1016\/j.molcel.2022.08.017","volume":"82","author":"M Deshpande","year":"2022","unstructured":"Deshpande M, Paniza T, Jalloul N, Nanjangud G, Twarowski J, Koren A, Zaninovic N, Zhan Q, Chadalavada K, Malkova A, Khiabanian H, Madireddy A, Rosenwaks Z, Gerhardt J (2022) Error-prone repair of stalled replication forks drives mutagenesis and loss of heterozygosity in haploinsufficient BRCA1 cells. Mol Cell 82(20):3781\u20133793e3787. https:\/\/doi.org\/10.1016\/j.molcel.2022.08.017","journal-title":"Mol Cell"},{"issue":"4","key":"4670_CR13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.celrep.2016.12.075","volume":"18","author":"VE Mgbemena","year":"2017","unstructured":"Mgbemena VE, Signer RAJ, Wijayatunge R, Laxson T, Morrison SJ, Ross TS (2017) Distinct Brca1 mutations differentially reduce hematopoietic stem cell function. Cell Rep 18(4):947\u2013960. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.075","journal-title":"Cell Rep"},{"key":"4670_CR14","doi-asserted-by":"publisher","first-page":"7505","DOI":"10.1038\/ncomms8505","volume":"6","author":"M Sedic","year":"2015","unstructured":"Sedic M, Skibinski A, Brown N, Gallardo M, Mulligan P, Martinez P, Keller PJ, Glover E, Richardson AL, Cowan J, Toland AE, Ravichandran K, Riethman H, Naber SP, N\u00e4\u00e4r AM, Blasco MA, Hinds PW, Kuperwasser C (2015) Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence. Nat Commun 6:7505. https:\/\/doi.org\/10.1038\/ncomms8505","journal-title":"Nat Commun"},{"key":"4670_CR15","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1038\/ncomms6496","volume":"5","author":"S Pathania","year":"2014","unstructured":"Pathania S, Bade S, Le Guillou M, Burke K, Reed R, Bowman-Colin C, Su Y, Ting DT, Polyak K, Richardson AL, Feunteun J, Garber JE, Livingston DM (2014) BRCA1 haploinsufficiency for replication stress suppression in primary cells. Nat Commun 5:5496. https:\/\/doi.org\/10.1038\/ncomms6496","journal-title":"Nat Commun"},{"issue":"43","key":"4670_CR16","doi-asserted-by":"publisher","first-page":"17773","DOI":"10.1073\/pnas.1110969108","volume":"108","author":"H Konishi","year":"2011","unstructured":"Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH (2011) Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc Natl Acad Sci USA 108(43):17773\u201317778. https:\/\/doi.org\/10.1073\/pnas.1110969108","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7432","key":"4670_CR17","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature11863","volume":"493","author":"MC Kottemann","year":"2013","unstructured":"Kottemann MC, Smogorzewska A (2013) Fanconi anaemia and the repair of Watson and Crick DNA crosslinks. Nature 493(7432):356\u2013363. https:\/\/doi.org\/10.1038\/nature11863","journal-title":"Nature"},{"issue":"3","key":"4670_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s10689-023-00331-6","volume":"22","author":"K Hu-Heimgartner","year":"2023","unstructured":"Hu-Heimgartner K, Lang N, Ayme A, Ming C, Combes JD, Chappuis VN, Vazquez C, Friedlaender A, Vuilleumier A, Bodmer A, Viassolo V, Sandoval JL, Chappuis PO, Labidi-Galy SI (2023) Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1\/BRCA2 germline pathogenic variants. A single center experience and review of the literature. Fam Cancer 22(3):283\u2013289. https:\/\/doi.org\/10.1007\/s10689-023-00331-6","journal-title":"Fam Cancer"},{"issue":"3","key":"4670_CR19","doi-asserted-by":"publisher","first-page":"941","DOI":"10.4143\/crt.2018.312","volume":"51","author":"BS Kwon","year":"2019","unstructured":"Kwon BS, Byun JM, Lee HJ, Jeong DH, Lee TH, Shin KH, Suh DS, Kim KH (2019) Clinical and genetic characteristics of BRCA1\/2 mutation in Korean ovarian Cancer patients: a Multicenter Study and Literature Review. Cancer Res Treat 51(3):941\u2013950. https:\/\/doi.org\/10.4143\/crt.2018.312","journal-title":"Cancer Res Treat"},{"issue":"3","key":"4670_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4048\/jbc.2013.16.3.245","volume":"16","author":"E Kang","year":"2013","unstructured":"Kang E, Kim SW (2013) The Korean hereditary breast cancer study: review and future perspectives. J Breast Cancer 16(3):245\u2013253. https:\/\/doi.org\/10.4048\/jbc.2013.16.3.245","journal-title":"J Breast Cancer"},{"issue":"12","key":"4670_CR21","doi-asserted-by":"publisher","first-page":"e1471","DOI":"10.1634\/theoncologist.2019-0272","volume":"24","author":"O Weitzner","year":"2019","unstructured":"Weitzner O, Yagur Y, Kadan Y, Beiner ME, Fishman A, Ben Ezry E, Amitai Komem D, Helpman L (2019) Chemotherapy toxicity in BRCA mutation carriers undergoing first-line platinum-based chemotherapy. Oncologist 24(12):e1471\u2013e1475. https:\/\/doi.org\/10.1634\/theoncologist.2019-0272","journal-title":"Oncologist"},{"issue":"1","key":"4670_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/igc.0000000000001144","volume":"28","author":"J Kotsopoulos","year":"2018","unstructured":"Kotsopoulos J, Willows K, Trat S, Kim RH, Volenik A, Sun P, Narod SA, Boyd J, May T (2018) BRCA mutation status is not Associated with increased hematologic toxicity among patients undergoing platinum-based chemotherapy for ovarian Cancer. Int J Gynecol cancer: Official J Int Gynecol Cancer Soc 28(1):69\u201376. https:\/\/doi.org\/10.1097\/igc.0000000000001144","journal-title":"Int J Gynecol cancer: Official J Int Gynecol Cancer Soc"},{"issue":"1","key":"4670_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ygyno.2019.04.009","volume":"154","author":"F Tomao","year":"2019","unstructured":"Tomao F, Musacchio L, Di Mauro F, Boccia SM, Di Donato V, Giancotti A, Perniola G, Palaia I, Muzii L, Benedetti Panici P (2019) Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients? Gynecol Oncol 154(1):138\u2013143. https:\/\/doi.org\/10.1016\/j.ygyno.2019.04.009","journal-title":"Gynecol Oncol"},{"key":"4670_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ejca.2020.12.007","volume":"145","author":"J Furlanetto","year":"2021","unstructured":"Furlanetto J, Mobus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lubbe K, Untch M, Salat C, Huober J, Klare P, Schmutzler R, Couch FJ, Lederer B, Gerber B, Zahm DM, Bauerfeind I, Nekljudova V, Hanusch C, Jackisch C, Link T, Hahnen E, Loibl S, Fasching PA (2021) Germline BRCA1\/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy. Eur J cancer (Oxford England: 1990) 145:44\u201352. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.007","journal-title":"Eur J cancer (Oxford England: 1990)"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04670-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04670-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04670-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T14:03:34Z","timestamp":1721311414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04670-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["4670"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04670-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,23]]},"assertion":[{"value":"26 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. This study was approved by the Institutional Review Board of KNUCH (KNUCH_07\u20130033). Written informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}